NUCALA achieved and maintained normal eosinophil levels

The reduction in blood eosinophils observed at Week 8 in the NUCALA 

group was maintained overall through Week 321,2

Blood eosinophil count ratio to baseline

Blood eosinophil count ratio to baseline line graph
Blood eosinophil count ratio to baseline line graph

Baseline: 1460 cells/μL

92%

reduction in eosinophils

at Week 32 vs placebo*

Week 32: 70 cells/μL

 

Results are descriptive. The clinical significance of these pharmacodynamic data is unknown.

 

Note: Mean normal blood eosinophil levels in a general population of subjects without confounding factors have been reported as 100 cells/µL (range: 34-257) and 107 cells/µL (5th, 95th percentile: 30, 395); levels vary based on age, sex, environmental exposures and comorbid conditions.3,4

*Placebo, 870 cells/μL at Week 32 (1350 cells/μL at baseline). Counts given as geometric mean.

NUCALA: The first and ONLY anti-IL-5 for hypereosinophilic syndrome (HES)

NUCALA targets interleukin 5 (IL-5)—the major cytokine responsible for the growth and differentiation, recruitment, activation, and survival of eosinophils.

NUCALA mechanism of action diagram
 
 
 
 

 

NUCALA mechanism of action diagram

The MOA of mepolizumab in HES has not been definitively established.

divider
divider

The role of eosinophils in health and HES

Eosinophils cell diagram
Eosinophils cell diagram

Role of eosinophils in maintaining health
includes
5:

  • Regulating the immune system
  • Tissue regeneration and repair
  • Host protection (eg, defending against
    parasitic infection)

In HES, hypereosinophilia is associated with
organ dysfunction or damage.
6

dosing icon